Nirmatrelvir plus ritonavir in COVID-19: a profile of its use-Reference-Cited by-同舟云学术

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use

Published:2022-12-06 Issue:2 Volume:39 Page:41-47
ISSN:1172-0360
Container-title:Drugs & Therapy Perspectives
language:en
Short-container-title:Drugs Ther Perspect

Author:

Blair Hannah A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40267-022-00971-1.pdf

Reference31 articles.

1. Islam T, Hasan M, Rahman MS, et al. Comparative evaluation of authorized drugs for treating Covid-19 patients. Health Sci Rep. 2022;5(4): e671.

2. Sanyaolu A, Okorie C, Marinkovic A, et al. Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review. Ther Adv Vaccines Immunother. 2022. https://doi.org/10.1177/25151355221097559.

3. World Health Organization. Therapeutics and COVID-19: living guideline. 2022. https://apps.who.int/iris/bitstream/handle/10665/362843/WHO-2019-nCoV-therapeutics-2022.5-eng.pdf. Accessed 15 Nov 2022.

4. Fenton C, Keam SJ. Emerging small molecule antivirals may fit neatly into COVID-19 treatment. Drugs Ther Perspect. 2022;38(3):112–26.

5. Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585–91.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics of nirmatrelvir in Chinese patients with COVID-19: Therapeutic drug monitoring and dosing regimen selection in clinical practice;International Journal of Antimicrobial Agents;2024-08

2. Integrated Surveillance of Disparities in Vaccination Coverage and Morbidity during the COVID-19 Pandemic: A Cohort Study in Southeast Sweden;Vaccines;2024-07-12

3. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial;Frontiers in Pharmacology;2024-05-27

4. Cholesterol and COVID-19—therapeutic opportunities at the host/virus interface during cell entry;Life Science Alliance;2024-02-22

5. Drug-drug interactions between COVID-19 drug therapies and antidepressants;Expert Opinion on Drug Metabolism & Toxicology;2023-11-30